Navigation Links
Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
Date:3/12/2008

69

------------- ------------- ------------- -------------

(3,465,036) (2,568,160) (9,035,414) (4,170,141)

Changes in

non-cash

working capital

items

Amounts

receivable 12,692 (167) (66,637) (52,696)

Prepaid

expenses 24,960 19,721 (13,397) (10,632)

Accounts

payable and

accrued

liabilities 1,147,682 1,295,766 451,125 871,628

------------- ------------- ------------- -------------

(2,279,702) (1,252,840) (8,664,323) (3,361,841)

Cash flows from

investing

activities

Investment in

patent rights (50,709) (81,217) (267,117) (344,777)

------------- ------------- ------------- -------------

Cash flows from

financing

activities

Issuance of

capital stock,

net of share

issue costs - - 19,588,150 12,086,713

Issuance of

capital stock

upon exercise

of stock

options - - - 6,000

Issuance of

capital stock

upon exercise

of warrants - - - 2,414

Cash of former

Bradmer upon

amalgamation - - - 563,405

Promissory note

due to related

party - - - (401,210)

Repurchase of

shares from

employee (800) - (800) -

------------- ------------- ------------- -------------

(800) - 19
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Notice of Bradmer Pharmaceuticals Conference Call
2. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
3. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
4. Bradmer announces additions to Scientific Advisory Board
5. Bradmer Medical Isotope Supply For Phase III Trial Secure
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer provides Phase III Neuradiab trial update and guidance
8. Bradmer announces management changes
9. NHP Announces Management Promotions
10. WellPoint Announces Appearances at Upcoming Conferences
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...na-Hong Kong experts concluded that there is a gen...d that SARS is transmitted to human beings through...inese Information Times newspaper on Thursday. T... civet cats, by the Center for Disease Control and...
... and adolescents are enjoying the health and socia...t many observers have noted problems related to// ... while sport medicine physicians have seen alarmin...hletes. The November/December issue of the Clinica...
...mp in funds to the tune of SFr25 million ($20 mill...e of Technology in Lausanne to invest in the creat...r of the brain. The joint venture, envisaged for ... power in children. Also research to lessen the im...
...officials have banned the sale of turbot after the...ish //at several of Beijing’s fish markets, report...d by Cao Jilin from Europe in 1992. Due to low re... on medicinal supplements, which sometime leave ha...
Other Medicine News:Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 3
(Date:10/6/2008)...a Presented at the American College of Gastroenter...g, ORLANDO, Fla., Oct. 6 /- Combined... American College of Gastroenterology Annual,Scien... that TAK-390MR,resulted in higher healing rates t...rades of erosive esophagitis (EE). TAK-390MR combi...
(Date:10/6/2008)...Data Presented at ACG Annual Scientific Conference...d Pharmaceuticals,(formerly Microbia) today announ...l studies delineating the role that cyclic guanosi...tinal pain. These studies,demonstrate that cGMP in...ntestinal hyperalgesia and desensitizes colonic af...
(Date:10/6/2008)...cuss Promising Research at The American College of...ing, WASHINGTON, Oct. 6 /- New resea...seniors was presented at The American College of,N...ctical Applications of,Probiotics in Health and Di...rics, aging, and nutrition discussed the potential...
(Date:10/6/2008)...MEETING, Pa., Oct. 6 /- Gen...ata from its second Phase 1,clinical trial of trod...e,for the treatment of type 2 diabetes and obesity...ted molecular target that controls the function,of... glucose and decrease,appetite. In the study, MSI-...
Breaking Medicine Technology:Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Elder Caregiving Site ShirleyBOARD com Wins WebAward for Outstanding Online Community 1587 1Elder Caregiving Site ShirleyBOARD com Wins WebAward for Outstanding Online Community 1587 2Fairness Coalition Applauds Senate Passage of Mental Health Parity Bill 1582 1US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness 324 1US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness 324 2US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness 324 3Pregnancy may slow not accelerate progression to AIDS 1581 1Pregnancy may slow not accelerate progression to AIDS 1581 2Pregnancy may slow not accelerate progression to AIDS 1581 3
... WIRE)--Apr 17, 2007 - Adnexus(TM),Therapeutics, I...ct,"CT-322: A specific VEGFR-2-blocking protein th... models comparable to pan-specific,tyrosine kinase...he,American Association for Cancer Research (AACR)...author is Irvith Carvajal, Ph.D., with,Eric Furfin...
...SS WIRE)--Apr 18, 2007 - Idera,Pharmaceuticals, In...f data for two new potential applications in oncol...(TLR9) at the Annual Meeting of,the American Assoc...s Angeles, CA, April 14-18, 2007. The first presen...s lead oncology candidate,IMO-2055, in combinatio...
Other Medicine Technology:Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 2Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 3Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 4Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 2Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 3Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 4
Bacterial/Viral Filters for Anesthesia and Respiratory Applications
Bacterial/Viral Filters for Anesthesia and Respiratory Applications
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours.
Medicine Products: